| Literature DB >> 20570567 |
Hetty J Bontkes1, María Moreno, Basav Hangalapura, Jelle J Lindenberg, Jan de Groot, Sinéad Lougheed, Hans J J van der Vliet, Alfons J M van den Eertwegh, Tanja D de Gruijl, B Mary E von Blomberg, Rik J Scheper.
Abstract
CD1d restricted, alpha-galactosylceramide (alphaGC) responsive invariant (i)NKT cells positively regulate immune responses. Both intravenous and intradermal administered alphaGC are known to activate iNKT cells. iNKT cells become unresponsive to a second intravenous alphaGC injection, whereas no data are available regarding potential anergy upon intradermal administration. Here, comparative analysis of two intradermal versus two intravenous injections in mice demonstrated that iNKT cell anergy was prevented by intradermal injection and when combined with a vaccine, superior tumor protection afforded by intradermally administered alphaGC. Moreover, human skin dendritic cells (DC) took up intradermally injected alphaGC and activated iNKT cells upon migration, while iNKT cells in human skin-draining lymph nodes expanded in response to alphaGC presented either by exogenously added DC or by CD1d positive antigen presenting cells in the lymph nodes. In conclusion, glycolipids such as alphaGC may greatly improve the efficacy of skin immunization strategies, targeting cutaneous and lymph node DC. Copyright 2010 Elsevier Inc. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20570567 DOI： 10.1016/j.clim.2010.04.019
Source DB: PubMed Journal: Clin Immunol ISSN： 1521-6616 Impact factor: 3.969